KORU Medical Systems Partners for Advancements in Nephrology Care
KORU Medical Systems (NASDAQ: KRMD), a prominent leader in the medical technology space, is excited to announce its collaboration with a global pharmaceutical manufacturer for a groundbreaking Phase III clinical trial. This clinical trial focuses on an expanded indication for an existing drug designed to treat a rare renal disorder, addressing the needs of a patient population of approximately 30,000 individuals. With around 300,000 infusions expected annually, this partnership signifies a pivotal moment in enhancing patient care.
Innovative Solutions in Drug Delivery
This development underscores KORU Medical's ongoing commitment to innovation and collaboration within the healthcare sector. The Phase III trial aims to thoroughly evaluate the safety, effectiveness, and overall performance of the drug therapy in managing complications related to kidney transplants. Such advancements are crucial as they highlight the importance of improving the quality of life for patients who face rare health challenges.
Growth in Subcutaneous Infusion Market
Linda Tharby, President and CEO of KORU Medical, expressed enthusiasm for the expanding large volume subcutaneous market, noting, "We continue to see growth in the overall large volume subcutaneous market with multiple new drugs entering clinical trials and several others receiving regulatory approval. With over 2 million infusions administered on the KORU Freedom Infusion System every year, KORU continues to be a leading collaboration partner for large volume subcutaneous drug therapies in both home and infusion clinic settings.”
Empowering Patients with Rare Renal Disorders
Tharby further emphasized the significance of the upcoming trial: "Assuming successful completion and results from this Phase III clinical trial, this drug’s expanded indication will give us access to a new patient base and enable the delivery of a therapy to improve the lives of those with rare renal disorder.” This forward-thinking approach ensures that patients receive the necessary treatments to enhance their health and well-being.
About KORU Medical Systems
KORU Medical Systems is dedicated to the development, manufacturing, and commercialization of innovative solutions in large volume subcutaneous infusion. Their products, such as the FREEDOM Syringe Infusion System—including the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers—have revolutionized patient care for self-administration or delivery in healthcare environments. The Freedom System has been a staple since its FDA clearance in 1994, continually evolving to meet the needs of patients. Furthermore, KORU Medical actively supports biopharmaceutical companies through its Novel Therapies division, providing tailored solutions for clinical trials and drug development processes.
Frequently Asked Questions
What is the main purpose of the Phase III trial conducted by KORU Medical?
The Phase III trial aims to evaluate the safety and efficacy of an expanded indication for an existing drug treatment for patients with renal disorders.
How many patients could potentially benefit from the new drug indication?
The trial is expected to help approximately 30,000 patients who are dealing with rare renal disorders.
What role does KORU Medical play in the subcutaneous infusion market?
KORU Medical is a leader in developing innovative subcutaneous infusion solutions, with significant annual infusion administration using their systems.
What are some products developed by KORU Medical Systems?
KORU Medical manufactures several infusion solutions, including the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers.
What does KORU Medical's Novel Therapies division do?
The Novel Therapies division supports biopharmaceutical companies in clinical trials and can customize infusion systems for various drug categories.
